Glenmark concludes post marketing surveillance (PMS) study on Favipiravir (FabiFlu®) in 1000+ COVID-19 patients, findings reinforce the drug’s safety and efficacy in real world settings
Newsroom
Glenmark Pharma reports revenue growth of 26% and PAT growth of 21% YoY for Q1 FY 2021-22
13 Aug 2021 | Read More
Glenmark inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets
2 Aug 2021 | Read More
Glenmark receives ANDA tentative approval for Nintedanib Capsules, 100 mg and 150 mg
25 Jun 2021 | Read More
Glenmark Pharmaceuticals receives ANDA approval for Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials
23 Jun 2021 | Read More
Glenmark launches Tiogiva®, becoming one of the first companies in the UK to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler
15 Jun 2021 | Read More
Glenmark releases interim data from PMS Study on Favipiravir
8 Jun 2021 | Read More
Glenmark Pharmaceuticals receives ANDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity on the 450 mg
4 Jun 2021 | Read More
Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg
1 Jun 2021 | Read More
Glenmark’s consolidated revenues grow 2.8% to Rs. 1,09,439 Mn in FY21
28 May 2021 | Read More
Glenmark Pharmaceuticals receives ANDA approval for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe
24 May 2021 | Read More
Glenmark launches Ryaltris®-AZ at an affordable price in India
3 May 2021 | Read More
Glenmark’s Ryaltris ® nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age
26 Apr 2021 | Read More
Glenmark Pharmaceuticals receives ANDA approval for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity.
24 Mar 2021 | Read More
Glenmark Pharmaceuticals receives ANDA approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 60 mg, 90 mg, and 120 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity
23 Mar 2021 | Read More
Glenmark and Bausch Health join together to commercialize RYALTRIS ™ nasal spray in Canada
22 Mar 2021 | Read More
Glenmark signs on Rohit Sharma as brand ambassador of Candid Powder
5 Mar 2021 | Read More
Glenmark receives ‘India Pharma Innovation of the Year’ Award from the Govt. of India
25 Feb 2021 | Read More
Glenmark’s Ryaltris®- innovative single nasal spray, ready to market in Russia
22 Feb 2021 | Read More
Glenmark launches SUTIB (Sunitinib) – priced 96% lower than the innovator brand. Reduces the risk of kidney cancer progression by 58%
16 Feb 2021 | Read More
Glenmark’s consolidated sales rises by 3.88% to Rs. 27,605.07 Mn. in Q3 FY 2020-21
12 Feb 2021 | Read More
Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Gel USP, 1%
11 Feb 2021 | Read More
Glenmark Pharmaceuticals receives ANDA approval for Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg
3 Feb 2021 | Read More
Glenmark Pharmaceuticals receives ANDA approval for Amphetamine Sulfate Tablets USP, 5 mg and 10 mg
28 Jan 2021 | Read More
Library
Profile – Chairman and Managing Director
With the idea of creating something unique, Glenn Saldanha took over the reins of the company and helped transform it into a global enterprise worth USD 1.48 billion with offices across 50 countries. Download Profile
Profile – Glenmark Pharmaceuticals
Research-driven, global and integrated pharmaceutical company which is driven to meet unmet medical needs and help pave a new way for a new world. Download Profile
For any media related queries, please email corpcomm@glenmarkpharma.com